Regorafenib
Stivarga
Sources
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7
Median PFS in months (95% CI) 4.8 (3.9, 5.7) 0.9 (0.9, 1.1) HR (95% CI) 0.27 (0.19, 0.39) ... Median OS in Months 17.4 (14.9, 20.2) 17.4 (12.3, 21.0) HR 0.91
Stivarga USPI boxed warning (hepatotoxicity) and section 14.2, Table 8, GRID (NCT01271712)
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT01271712
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib
ClinicalTrials.gov API v2 record, retrieved 2026-11-07